Sacubitril/Valsartan better than ACEI/ARB in lowering mortality risk in HFrEF patients with CKD
A recent study published in the Cardiovascular Drugs and Therapy Journal found that sacubitril/valsartan has lower all-cause mortality in patients with heart failure and reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) over a 12-month follow-up period. Wei-Chieh Lee and team undertook this study to investigate the differential effects of sacubitril/valsartan and angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEIs/ARBs) on clinical and renal outcomes in CKD patients HFrEF.
The study enrolled 3735 patients with HFrEF and a mean left ventricular ejection fraction of 27.56% who had been prescribed sacubitril/valsartan or ACEI/ARB. The study used propensity score matching to compare the clinical and renal outcomes between the two groups of patients with and without CKD over the 12-month follow-up period.
The highlights of the study were:
There were no significant differences in clinical and renal outcomes between the sacubitril/valsartan and ACEI/ARB groups in patients without CKD.
In the patient population that had CKD and were prescribed ACEI/ARB, the study found a 14.89% incidence of all-cause mortality over the 12-month follow-up period. On the other hand, in patients with CKD who were prescribed sacubitril/valsartan, the study found a 10.50% incidence of all-cause mortality over the same follow-up period, which was lower.
The incidence of acute kidney injury (AKI), heart failure hospitalization, and cardiovascular mortality did not differ between the two groups.
The study concludes that sacubitril/valsartan may have a lower all-cause mortality compared to ACEI/ARB in symptomatic HFrEF patients with CKD. However, the Authors of this study also noted that further prospective randomized studies are warranted to confirm these findings.
Source:
Lee, W.-C., Liao, T.-W., Chen, T.-Y., Fang, H.-Y., Fang, Y.-N., Chen, H.-C., Lin, Y.-S., Chang, S.-H., & Chen, M.-C. (2023). Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease. In Cardiovascular Drugs and Therapy. Springer Science and Business Media LLC. https://doi.org/10.1007/s10557-022-07421-0
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.